Evidence map›Paper›PMID 24929655›Full record

ReviewNeuromolecular medicine2014

Functions of the CB1 and CB 2 receptors in neuroprotection at the level of the blood-brain barrier.

Esmée Vendel, Elizabeth C M de Lange

Abstract readReview
PubMed Publisher
In one paragraph

Review in Neuromolecular medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Ageing, Neurodegeneration and the Endocannabinoid System.Current topics in behavioral neurosciences · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Development and evaluation of deuterated [EJNMMI radiopharmacy and chemistry · 2024
    Article
  9. Review
  10. Potential of CBD Acting on Cannabinoid Receptors CBInternational journal of molecular sciences · 2024
    Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Molecular Landscape of Tourette's Disorder.International journal of molecular sciences · 2023
    Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Esmée VendelDivision of Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Einsteinweg 55, 2333CC, PO Box 9502, 2300 RA, Leiden, The Netherlands.
Elizabeth C M de Lange
Centre for Human Drug Research · NLLeiden University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cannabinoid (CB) receptors are the main targets of the cannabinoids, which include plant cannabinoids, endocannabinoids and synthetic cannabinoids. Over the last few years, accumulated evidence has suggested a role of the CB receptors in neuroprotection. The blood-brain barrier (BBB) is an important brain structure that is essential for neuroprotection. A link between the CB receptors and the BBB is thus likely, but this possible connection has only recently gained attention. Cannabinoids and the BBB share the same mechanisms of neuroprotection and both protect against excitotoxicity (CB1), cell death (CB1), inflammation (CB2) and oxidative stress (possibly CB independent)-all processes that also damage the BBB. Several examples of CB-mediated protection of the BBB have been found, such as inhibition of leukocyte influx and induction of amyloid beta efflux across the BBB. Moreover, the CB receptors were shown to improve BBB integrity, particularly by restoring the tightness of the tight junctions. This review demonstrated that both CB receptors are able to restore the BBB and neuroprotection, but much uncertainty about the underlying signaling cascades still exists and further investigation is needed.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAnimalsAntioxidantsBlood-Brain BarrierCalcium SignalingCannabinoidsChemotaxis, LeukocyteEncephalitisEndocannabinoidsEndothelial CellsHumansNeurogenesisNeuroimmunomodulationNeuroprotective AgentsNeurotoxinsAmyloid beta-PeptidesAntioxidantsCannabinoidsEndocannabinoidsNeuroprotective AgentsNeurotoxinsReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2

Identifiers

PMID24929655
OpenAlexW2070194440

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.